It is known that IL-6 levels are increased in obesity, type 2 diabetes, NAFLD, and several metabolic states that are associated with an elevated SLC13A5 expression [26,79,80,81]. This evidence concerns the gene SLC13A5 and metabolic dysfunction-associated steatotic liver disease.